TWI695838B - 作爲pde1抑制劑之咪唑並吡酮 - Google Patents

作爲pde1抑制劑之咪唑並吡酮 Download PDF

Info

Publication number
TWI695838B
TWI695838B TW105113074A TW105113074A TWI695838B TW I695838 B TWI695838 B TW I695838B TW 105113074 A TW105113074 A TW 105113074A TW 105113074 A TW105113074 A TW 105113074A TW I695838 B TWI695838 B TW I695838B
Authority
TW
Taiwan
Prior art keywords
pyridine
methyl
imidazo
piperan
tetrahydro
Prior art date
Application number
TW105113074A
Other languages
English (en)
Chinese (zh)
Other versions
TW201700477A (zh
Inventor
洋 凱爾勒
勞思慕森 拉斯 更
摩頓 藍格德
米可爾 潔西
維塔 保羅 喬治 拜拉
卡斯登 攸爾
Original Assignee
丹麥商H 朗德貝克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 丹麥商H 朗德貝克公司 filed Critical 丹麥商H 朗德貝克公司
Publication of TW201700477A publication Critical patent/TW201700477A/zh
Application granted granted Critical
Publication of TWI695838B publication Critical patent/TWI695838B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW105113074A 2015-04-30 2016-04-27 作爲pde1抑制劑之咪唑並吡酮 TWI695838B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA201500261 2015-04-30
DKPA201500261 2015-04-30
DKPA201500666 2015-10-29
DKPA201500666 2015-10-29
DKPA201600202 2016-04-04
DKPA201600202 2016-04-04

Publications (2)

Publication Number Publication Date
TW201700477A TW201700477A (zh) 2017-01-01
TWI695838B true TWI695838B (zh) 2020-06-11

Family

ID=55910242

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105113074A TWI695838B (zh) 2015-04-30 2016-04-27 作爲pde1抑制劑之咪唑並吡酮

Country Status (42)

Country Link
US (4) US20160318939A1 (enExample)
EP (1) EP3288944B1 (enExample)
JP (1) JP6663930B2 (enExample)
KR (1) KR102605759B1 (enExample)
CN (1) CN107531714B (enExample)
AU (1) AU2016256573B2 (enExample)
BR (1) BR112017023182B1 (enExample)
CA (1) CA2983563A1 (enExample)
CL (1) CL2017002719A1 (enExample)
CO (1) CO2017010399A2 (enExample)
CY (1) CY1121806T1 (enExample)
DK (1) DK3288944T3 (enExample)
DO (1) DOP2017000254A (enExample)
EA (1) EA031946B1 (enExample)
EC (1) ECSP17072228A (enExample)
ES (1) ES2735422T3 (enExample)
GE (2) GEP20207058B (enExample)
GT (1) GT201700223A (enExample)
HK (1) HK1252098B (enExample)
HR (1) HRP20191180T1 (enExample)
HU (1) HUE044244T2 (enExample)
IL (1) IL255316B (enExample)
JO (1) JO3627B1 (enExample)
LT (1) LT3288944T (enExample)
MA (1) MA41977B1 (enExample)
ME (1) ME03414B (enExample)
MX (1) MX375737B (enExample)
MY (1) MY182382A (enExample)
PE (1) PE20180121A1 (enExample)
PH (1) PH12017501990B1 (enExample)
PL (1) PL3288944T3 (enExample)
PT (1) PT3288944T (enExample)
RS (1) RS59051B1 (enExample)
RU (1) RU2712219C2 (enExample)
SG (1) SG11201708822PA (enExample)
SI (1) SI3288944T1 (enExample)
SM (1) SMT201900393T1 (enExample)
TN (1) TN2017000428A1 (enExample)
TW (1) TWI695838B (enExample)
UA (1) UA123050C2 (enExample)
WO (1) WO2016174188A1 (enExample)
ZA (1) ZA201706847B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
CN109843884B (zh) 2016-10-18 2022-03-04 H.隆德贝克有限公司 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
EP3532064B1 (en) 2016-10-28 2020-07-29 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
KR20190077349A (ko) 2016-10-28 2019-07-03 하. 룬드벡 아크티에셀스카브 이미다조피라지논의 투여를 포함하는 병용 치료
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
JP7254078B2 (ja) 2017-11-27 2023-04-07 ダート・ニューロサイエンス・エルエルシー Pde1阻害剤としての置換フラノピリミジン化合物
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
EP3728250A1 (en) 2017-12-20 2020-10-28 H. Lundbeck A/S PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS
EP3802545A4 (en) 2018-05-25 2022-03-16 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
WO2020210614A1 (en) 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Organic compounds
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135767A1 (en) * 2004-12-21 2006-06-22 Jun Feng Dipeptidyl peptidase inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
WO2004099211A1 (de) 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
DE602005014964D1 (de) * 2004-04-02 2009-07-30 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
US20080194592A1 (en) * 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規使用
DK2152712T3 (da) 2007-05-11 2012-03-26 Pfizer Aminoheterocykliske fobindelser
AU2008329072A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20110383A1 (es) * 2008-09-08 2011-07-15 Boehringer Ingelheim Int Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
BRPI0922809A2 (pt) * 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
WO2010144711A2 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
LT3339323T (lt) 2010-08-12 2020-02-10 Eli Lilly And Company Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas
RU2603140C2 (ru) 2010-09-20 2016-11-20 Айронвуд Фармасьютикалз, Инк. Соединения имидазотриазинона
EP2619204A4 (en) 2010-09-21 2014-08-27 Merck Sharp & Dohme TRIAZOLOPYRAZINONE AS P2X7 RECEPTOR ANTAGONISTS
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
HK1211023A1 (zh) * 2011-10-10 2016-05-13 H. Lundbeck A/S 具有咪唑并吡嗪骨架pde9i
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
JP2013166727A (ja) 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
AU2013277294C1 (en) 2012-06-18 2018-02-08 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
PL2970279T3 (pl) 2013-03-15 2021-05-31 Intra-Cellular Therapies, Inc. Związki organiczne
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
GEAP201814248A (en) 2014-02-19 2018-04-10 H Lundbeck As 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
US20180044343A1 (en) 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
TW201643167A (zh) 2015-04-22 2016-12-16 H 朗德貝克公司 作爲pde1抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP2018531889A (ja) 2015-08-12 2018-11-01 ハー・ルンドベック・アクチエゼルスカベット Bace1阻害剤としての2−アミノ−3−フルオロ−3−(フルオロメチル)−6−メチル−6−フェニル−3,4,5,6−テトラヒドロピリジン
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
CN109843884B (zh) 2016-10-18 2022-03-04 H.隆德贝克有限公司 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
KR20190077349A (ko) 2016-10-28 2019-07-03 하. 룬드벡 아크티에셀스카브 이미다조피라지논의 투여를 포함하는 병용 치료
EP3532064B1 (en) 2016-10-28 2020-07-29 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135767A1 (en) * 2004-12-21 2006-06-22 Jun Feng Dipeptidyl peptidase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
1. CAS Registry Number: 1340877-13-5、1296334-75-2,Date Entered STN:2011.11.04、2011.05.18。
1.CAS Registry Number: 1340877-13-5、1296334-75-2,Date Entered STN:2011.11.04、2011.05.18 *

Also Published As

Publication number Publication date
RU2017137514A3 (enExample) 2019-07-17
HRP20191180T1 (hr) 2019-10-04
US20190062335A1 (en) 2019-02-28
ME03414B (me) 2020-01-20
HUE044244T2 (hu) 2019-10-28
EP3288944A1 (en) 2018-03-07
ECSP17072228A (es) 2018-02-28
CY1121806T1 (el) 2020-07-31
CN107531714A (zh) 2018-01-02
EA201792157A1 (ru) 2018-03-30
US11472810B2 (en) 2022-10-18
GT201700223A (es) 2018-12-19
PT3288944T (pt) 2019-07-19
AU2016256573A1 (en) 2017-12-14
US20210238182A1 (en) 2021-08-05
CN107531714B (zh) 2019-07-19
LT3288944T (lt) 2019-07-25
MY182382A (en) 2021-01-22
RS59051B1 (sr) 2019-08-30
HK1252098A1 (en) 2019-05-17
PL3288944T3 (pl) 2019-11-29
CO2017010399A2 (es) 2018-01-05
US10011606B2 (en) 2018-07-03
ZA201706847B (en) 2019-01-30
DOP2017000254A (es) 2018-01-15
SG11201708822PA (en) 2017-11-29
BR112017023182A2 (enExample) 2018-10-02
MX375737B (es) 2025-03-06
PE20180121A1 (es) 2018-01-18
RU2712219C2 (ru) 2020-01-27
CL2017002719A1 (es) 2018-04-20
KR20170140216A (ko) 2017-12-20
KR102605759B1 (ko) 2023-11-23
MA41977A (fr) 2018-07-23
PH12017501990A1 (en) 2018-03-26
CA2983563A1 (en) 2016-11-03
EP3288944B1 (en) 2019-06-12
ES2735422T3 (es) 2019-12-18
AU2016256573B2 (en) 2019-11-21
SMT201900393T1 (it) 2019-09-09
SI3288944T1 (sl) 2019-08-30
EA031946B1 (ru) 2019-03-29
JO3627B1 (ar) 2020-08-27
IL255316A0 (en) 2017-12-31
JP2018514552A (ja) 2018-06-07
TN2017000428A1 (en) 2019-04-12
PH12017501990B1 (en) 2021-01-13
JP6663930B2 (ja) 2020-03-13
US20160318939A1 (en) 2016-11-03
US10858362B2 (en) 2020-12-08
GEP20207058B (en) 2020-01-27
IL255316B (en) 2021-10-31
RU2017137514A (ru) 2019-05-31
MA41977B1 (fr) 2019-08-30
MX2017013785A (es) 2018-03-27
DK3288944T3 (da) 2019-07-22
US20170291903A1 (en) 2017-10-12
TW201700477A (zh) 2017-01-01
HK1252098B (en) 2020-02-07
GEAP201914615A (en) 2019-09-25
WO2016174188A1 (en) 2016-11-03
BR112017023182B1 (pt) 2023-10-31
UA123050C2 (uk) 2021-02-10

Similar Documents

Publication Publication Date Title
TWI695838B (zh) 作爲pde1抑制劑之咪唑並吡酮
CN107531713B (zh) 作为pde1抑制剂的咪唑并三嗪酮
TW201920115A (zh) 化合物、組合物及方法
CN109803653A (zh) 包括给予咪唑并吡嗪酮的组合治疗
TWI729109B (zh) 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
CN109803658A (zh) 包含用于治疗精神疾病和/或认知障碍的咪唑并吡嗪酮的组合治疗
OA18771A (en) Imidazopyrazinones as PDE1 Inhibitors
HK40005946B (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
HK40005946A (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees